Impact of Staphylococcus aureus colonization and skin abscesses on formation of human anti-αGal antibodies.

IF 5.5 3区医学 Q1 IMMUNOLOGY

Medical Microbiology and Immunology Pub Date : 2025-05-13 DOI:10.1007/s00430-025-00833-3

Jens Magnus Bernth Jensen, Khoa Manh Dinh, Lotte Hindhede, Lise Tornvig Erikstrup, Annette Gudmann Hansen, Kirstine Mejlstrup Hymøller, Sisse Rye Ostrowski, Ole B V Pedersen, Stig Hill Christiansen, Uffe B Skov Sørensen, Steffen Thiel, Christian Erikstrup

{"title":"Impact of Staphylococcus aureus colonization and skin abscesses on formation of human anti-αGal antibodies.","authors":"Jens Magnus Bernth Jensen, Khoa Manh Dinh, Lotte Hindhede, Lise Tornvig Erikstrup, Annette Gudmann Hansen, Kirstine Mejlstrup Hymøller, Sisse Rye Ostrowski, Ole B V Pedersen, Stig Hill Christiansen, Uffe B Skov Sørensen, Steffen Thiel, Christian Erikstrup","doi":"10.1007/s00430-025-00833-3","DOIUrl":null,"url":null,"abstract":"<p><p>IgG antibodies against terminal galactose-α-1,3-galactose (anti-αGal antibodies) are naturally occurring in humans, but their origins remain poorly understood. These antibodies target various microorganisms including Staphylococcus aureus, a common nasal commensal and the major cause of skin abscesses. This study investigates the impact of S. aureus colonization and abscess events on plasma anti-αGal antibody levels. We measured plasma anti-αGal antibody levels using a quantitative immunoassay in: (i) 101 pairs of healthy individuals with and without nasal S. aureus colonization, (ii) 106 healthy individuals before and after abscess formation, and (iii) 43 patients with recurrent skin abscesses compared with 75 patient controls and 60 healthy controls. We observed a 35% reduction (95%CI: 7-54%) in anti-αGal antibody levels in nasal S. aureus carriers. Conversely, we found a 30% increase (95%CI: 4-66%) in individuals within 187 days post-skin abscess, and patients with recurrent skin abscesses exhibited 81% higher (95%CI: 14-190%) levels than patient controls, and 110% higher (95%CI: 39-230%) than healthy controls. This study suggests that skin abscesses lead to elevated plasma anti-αGal antibody levels and that these antibodies might convey or correlate with mucosal immunity to S. aureus.</p>","PeriodicalId":18369,"journal":{"name":"Medical Microbiology and Immunology","volume":"214 1","pages":"23"},"PeriodicalIF":5.5000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075334/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Microbiology and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00430-025-00833-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

IgG antibodies against terminal galactose-α-1,3-galactose (anti-αGal antibodies) are naturally occurring in humans, but their origins remain poorly understood. These antibodies target various microorganisms including Staphylococcus aureus, a common nasal commensal and the major cause of skin abscesses. This study investigates the impact of S. aureus colonization and abscess events on plasma anti-αGal antibody levels. We measured plasma anti-αGal antibody levels using a quantitative immunoassay in: (i) 101 pairs of healthy individuals with and without nasal S. aureus colonization, (ii) 106 healthy individuals before and after abscess formation, and (iii) 43 patients with recurrent skin abscesses compared with 75 patient controls and 60 healthy controls. We observed a 35% reduction (95%CI: 7-54%) in anti-αGal antibody levels in nasal S. aureus carriers. Conversely, we found a 30% increase (95%CI: 4-66%) in individuals within 187 days post-skin abscess, and patients with recurrent skin abscesses exhibited 81% higher (95%CI: 14-190%) levels than patient controls, and 110% higher (95%CI: 39-230%) than healthy controls. This study suggests that skin abscesses lead to elevated plasma anti-αGal antibody levels and that these antibodies might convey or correlate with mucosal immunity to S. aureus.

查看原文本刊更多论文

金黄色葡萄球菌定植和皮肤脓肿对人抗α - gal抗体形成的影响。

抗末端半乳糖-α-1,3-半乳糖的IgG抗体（抗α- gal抗体）在人类中自然存在，但其来源尚不清楚。这些抗体针对各种微生物，包括金黄色葡萄球菌，一种常见的鼻共生菌和皮肤脓肿的主要原因。本研究探讨金黄色葡萄球菌定殖和脓肿事件对血浆抗α - gal抗体水平的影响。我们使用定量免疫法测量了血浆抗α - gal抗体水平：(i) 101对有或没有鼻腔金黄色葡萄球菌定植的健康个体，（ii） 106名健康个体在脓肿形成前后，以及（iii） 43名复发性皮肤脓肿患者，与75名患者对照和60名健康对照进行比较。我们观察到鼻金黄色葡萄球菌携带者抗α gal抗体水平降低35% （95%CI: 7-54%）。相反，我们发现在皮肤脓肿后187天内个体中有30%的增加（95%CI: 4-66%），复发性皮肤脓肿患者的水平比对照组高81% (95%CI: 14-190%)，比健康对照组高110% （95%CI: 39-230%）。本研究提示皮肤脓肿导致血浆抗α - gal抗体水平升高，这些抗体可能传递或与对金黄色葡萄球菌的粘膜免疫有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Microbiology and Immunology 医学-免疫学

CiteScore

10.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Medical Microbiology and Immunology (MMIM) publishes key findings on all aspects of the interrelationship between infectious agents and the immune system of their hosts. The journal´s main focus is original research work on intrinsic, innate or adaptive immune responses to viral, bacterial, fungal and parasitic (protozoan and helminthic) infections and on the virulence of the respective infectious pathogens. MMIM covers basic, translational as well as clinical research in infectious diseases and infectious disease immunology. Basic research using cell cultures, organoid, and animal models are welcome, provided that the models have a clinical correlate and address a relevant medical question. The journal also considers manuscripts on the epidemiology of infectious diseases, including the emergence and epidemic spreading of pathogens and the development of resistance to anti-infective therapies, and on novel vaccines and other innovative measurements of prevention. The following categories of manuscripts will not be considered for publication in MMIM: submissions of preliminary work, of merely descriptive data sets without investigation of mechanisms or of limited global interest, manuscripts on existing or novel anti-infective compounds, which focus on pharmaceutical or pharmacological aspects of the drugs, manuscripts on existing or modified vaccines, unless they report on experimental or clinical efficacy studies or provide new immunological information on their mode of action, manuscripts on the diagnostics of infectious diseases, unless they offer a novel concept to solve a pending diagnostic problem, case reports or case series, unless they are embedded in a study that focuses on the anti-infectious immune response and/or on the virulence of a pathogen.